Cargando…

Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia

Detalles Bibliográficos
Autores principales:	Zhang, Meili, Griner, Lesley A Mathews, Ju, Wei, Duveau, Damien Y, Guha, Rajarshi, Petrus, Michael, Wen, Bernard, Maeda, Michiyuki, Shinn, Paul, Ferrer, Marc, Conlon, Kevin C, Bamford, Richard, O'Shea, John J, Thomas, Craig J, Waldmann, Thomas A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4577772/ http://dx.doi.org/10.1186/1742-4690-12-S1-O42

Ejemplares similares

Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model
por: Yu, Ping, et al.
Publicado: (2014)

Enhanced efficacy of JAK1 inhibitor with mTORC1/C2 targeting in smoldering/chronic adult T cell leukemia
por: Daenthanasanmak, Anusara, et al.
Publicado: (2020)

Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors
por: Waibel, Michaela, et al.
Publicado: (2013)

Bcl-xL in neuroprotection and plasticity
por: Jonas, Elizabeth A., et al.
Publicado: (2014)

Prognostic significance of Bcl-xL expression and efficacy of Bcl-xL targeting therapy in urothelial carcinoma
por: Yoshimine, S, et al.
Publicado: (2013)

Nutritional Regulators of Bcl-xL in the Brain
por: Park, Han-A, et al.
Publicado: (2018)

Targeting BCL-XL in fibrolamellar hepatocellular carcinoma
por: Shebl, Bassem, et al.
Publicado: (2022)

Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Yosef, Reut, et al.
Publicado: (2016)

Bcl-XL but Not Bcl-2 Is a Potential Target in Medulloblastoma Therapy
por: Westhoff, Mike-Andrew, et al.
Publicado: (2022)

Mimicking Cdk2 phosphorylation of Bcl-xL at Ser73 results in caspase activation and Bcl-xL cleavage
por: Seng, NS, et al.
Publicado: (2016)

Combination of 9-aminoacridine with Campath-1H provides effective therapy for a murine model of adult T-cell leukemia
por: Ju, Wei, et al.
Publicado: (2014)

JAK2(V617F) Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL
por: Guo, Jun, et al.
Publicado: (2015)

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
por: He, Yonghan, et al.
Publicado: (2020)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1
por: Ow, Thomas J., et al.
Publicado: (2019)

Synthetic Lethal Interaction with BCL-XL Blockade Deepens Response to Cetuximab in Patient-Derived Models of Metastatic Colorectal Cancer
por: Leto, Simonetta M., et al.
Publicado: (2023)

Bcl-XL and Bcl-2 repress a common pathway of cell death
Publicado: (1995)

Targeting BCL-W and BCL-XL as a therapeutic strategy for Hodgkin lymphoma
por: Adams, Clare M., et al.
Publicado: (2019)

BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2020)

Bcl-XL Inhibits Membrane Permeabilization by Competing with Bax
por: Billen, Lieven P, et al.
Publicado: (2008)

Bcl-xL as a Modulator of Senescence and Aging
por: Mas-Bargues, Cristina, et al.
Publicado: (2021)

Bcl-xL: A Focus on Melanoma Pathobiology
por: Lucianò, Anna Maria, et al.
Publicado: (2021)

Involvement of Bcl-xL in Neuronal Function and Development
por: Bas, Julie, et al.
Publicado: (2021)

The Role of Bcl-xL Protein in Viral Infections
por: Wyżewski, Zbigniew, et al.
Publicado: (2021)

Roles and Regulation of BCL-xL in Hematological Malignancies
por: Morales-Martínez, Mario, et al.
Publicado: (2022)

Advances in Bcl-xL Research 2.0
por: Kervadec, Joann, et al.
Publicado: (2023)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Large-scale pharmacological profiling of 3D tumor models of cancer cells
por: Mathews Griner, Lesley A, et al.
Publicado: (2016)

Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization
por: Saxena, Nishant, et al.
Publicado: (2013)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Inhibition of Bcl-xL prevents pro-death actions of ΔN-Bcl-xL at the mitochondrial inner membrane during glutamate excitotoxicity
por: Park, Han-A, et al.
Publicado: (2017)

Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

Inhibition of Ceramide Metabolism Sensitizes Human Leukemia Cells to Inhibition of BCL2-Like Proteins
por: Casson, Lavona, et al.
Publicado: (2013)

Dynamics of Bcl-xL in Water and Membrane: Molecular Simulations
por: Maity, Atanu, et al.
Publicado: (2013)

Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin
por: Baranski, Zuzanna, et al.
Publicado: (2015)

Regulation of apoptosis by an intrinsically disordered region of Bcl-xL
por: Follis, Ariele Viacava, et al.
Publicado: (2018)

The Role of Bcl-xL Protein Research in Veterinary Oncology
por: Pawlak, Aleksandra, et al.
Publicado: (2020)

Selective Vulnerability of Senescent Glioblastoma Cells to BCL-XL Inhibition
por: Rahman, Masum, et al.
Publicado: (2022)

Bcl-xL activity influences outcome of the mitotic arrest
por: Suleimenov, M., et al.
Publicado: (2022)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_71m3q2qub9nu4uimeli35rvonl